Zenas BioPharma, Inc. ZBIO

ZBIO Company Overview

Zenas BioPharma, Inc. is a clinical-stage biotechnology company focused on developing and commercializing immunology-based therapeutics for autoimmune and inflammatory diseases. The company operates within the biopharmaceutical industry, with an emphasis on antibody therapeutics and precision immunology. Its primary value driver is the development of novel biologic candidates targeting immune pathways associated with severe chronic diseases, particularly those with unmet medical needs in rheumatology, nephrology, and related autoimmune indications.

The company’s lead asset is obexelimab, a bifunctional monoclonal antibody designed to inhibit B-cell activity by targeting both CD19 and FcγRIIb pathways. Zenas BioPharma has positioned itself around acquiring and advancing differentiated late-preclinical and clinical-stage immunology assets with global commercial potential. The company was founded in 2020 and has expanded through strategic licensing arrangements and capital raises involving biotechnology-focused investors. Public filings and investor materials indicate that the company’s strategy centers on efficient clinical development, global regulatory execution, and selective partnering opportunities.